

International Journal of Research in MEDICAL SCIENCE



ISSN Print: 2664-8733
ISSN Online: 2664-8741
Impact Factor: RJIF 8
IJRMS 2023; 5(1): 25-28
www.medicalpaper.net
Received: 05-04-2023
Accepted: 15-05-2023

Dr. Faraz Khan
Junior Resident, Saphthagiri
Institute of Medical Sciences
and Research Center,
Bangalore, Karnataka, India

An observational study assessing correlation between anemia and left ventricular hypertrophy in chronic kidney disease patients

Dr. Faraz Khan

DOI: <https://doi.org/10.33545/26648733.2023.v5.i1a.43>

Abstract

Aim: To calculate left ventricular mass index in patients of chronic kidney disease stage III-V having haemoglobin level <11 g/dl and to demonstrate development of left ventricular hypertrophy early in chronic kidney disease patients with mild to moderate anemia.

Methods: This study was done over one year on 100 patients of CKD (stage III to V), aged 15-80 years, who had elevated serum creatinine and reduced glomerular filtration rate, haemoglobin <11 gm/dl with ultrasonographic evidence of renal parenchymal disease grade >2. The patients were assessed based on clinical history and a number of laboratory parameters including blood urea, serum creatinine, calcium, inorganic phosphorus, serum electrolytes, iPTH level, Hb, Hct, glomerular filtration rate and left ventricular mass index.

Results: Majority % of the study population i.e. 68% was male, 32% was female. Most of the male patient, i.e. 73.52% of the study population, have abnormal left ventricular mass index (135 g/m² is taken as normal value for male patients). Majority of female patients i.e., 87.5% have abnormal left ventricular mass index. 34% patients belonged to 46-60 years age group. There was strong correlation between Anemia and left ventricular mass index in both male and female patients. 17 out of 22 patients who were diabetic are having abnormal LVMI, whereas 66 out of 78 non-diabetic patients have abnormal LVMI, so there is no correlation between DM and LVMI.

Conclusion: Anemia was widely prevalent in our CKD patients. Severity of anaemia is correlated to left ventricular hypertrophy in these patients. Hence correction of anaemia early in these groups of patients can halt or prevent cardiovascular morbidity and mortality.

Keywords: CKD, RPD, glomerular filtration rate, left ventricular mass index, intact parathormone

Introduction

The association of anemia with chronic kidney disease (CKD) has been recognized since the early 19th century. Moreover, various studies done over the years have shown not only a higher incidence of anemia, but also a significantly higher incidence of cardiac complications, particularly left ventricular hypertrophy in chronic kidney disease patients [1, 2]. In chronic kidney disease patients, various uremia-related risk factors for cardiovascular disease includes anemia, hyperparathyroidism, abnormalities of mineral metabolism, acidosis, of note, association of anemia have been consistently described in all population of kidney disease. Anemia is defined as decrease in either percentage of RBC (hematocrit) or decrease in haemoglobin concentration in sample of venous blood when compared to reference values. In our study reference value is taken as 11 g/dl for both male and female. Anemia of renal failure mainly caused by lack of sufficient quantity of endogenous erythropoietin production, partially due to iron deficiency which can be attributed to increased demand due to increased erythropoiesis in response to exogenous EPO, gastrointestinal bleed, ongoing blood loss with dialyzer and tubing and due to frequent sampling and Venipuncture. Anemia has been cited as an independent risk factor for the development of left ventricular hypertrophy (Left ventricular hypertrophy) in chronic kidney disease patients [3].

Anemia leads to hemodynamic as well as non-hemodynamic adaptation. Non-hemodynamic adaptation includes increase in erythropoietin hormone and intraerythrocytic 2, 3 DPG. Whereas hemodynamic adaptation takes place when Hb is <10 g/dl, includes increase cardiac

Corresponding Author:
Dr. Faraz Khan
Junior Resident, Saphthagiri
Institute of Medical Sciences
and Research Center,
Bangalore, Karnataka, India

preload and reduced SVR, both of which leads to high cardiac output, which if remains for long term leads to left ventricle remodelling (Initial dilatation and subsequent hypertrophy). Left ventricular hypertrophy is premature CVD that develop rapidly during progression of chronic kidney disease and is strong indicator of mortality in patient with ESRD. It is known that anemia is a strong predictor of development of left ventricular hypertrophy and morbidity and mortality in ESRD [4]. Left Ventricular Hypertrophy (LVH) is a frequent occurrence in patients with CKD and is an important adverse prognostic indicator [5, 6]. Anaemia is also frequent finding in CKD patients and is an important determinant of cardiac hypertrophy which can be associated with progressive LV dilation, new-onset cardiac failure, and death.⁷ There are very few studies done in India which has documented an association between the severity of anemia and left ventricular hypertrophy (LVH) in CKD patients. The aim and objective of this study were to calculate left ventricular mass index in patients of chronic kidney disease stage III-V having hemoglobin level <11 g/dl and to demonstrate development of left ventricular hypertrophy early in chronic kidney disease patients with mild to moderate anemia.

Material and Methods

A cross-sectional study conducted over 100 patients of either sex, age group of 15 to 80 years, from all socioeconomic status, admitted over a period of one year. Diagnosed as CKD patients with varying degrees of renal failure (grade III to V) with ultrasonographic evidence of renal parenchymal disease grade II or more and haemoglobin level <11 g% diabetic or non-diabetic, hypertensive or non-hypertensive and whether the patients were on dialysis or erythropoietin replacement or not. Out of 100 patients, 50 patients were hypertensive (controlled on medications). They were diagnosed as hypertensive between 2 to 4 years before commencing our study. Patients with post-renal transplant status and those with uncontrolled hypertension who are known case of hypertrophic obstructive cardiomyopathy, rheumatic heart disease etc. were excluded from the study.

Investigations

Investigations included Hb, HCT, blood urea, serum creatinine, calcium, inorganic phosphorus, bicarbonate, serum electrolytes, iPTH level, urine chest X-ray, renal ultrasound for kidney size and echotexture, left ventricular mass index calculation by Modified Devereux formula using electrocardiogram. Initial assessment included detailed clinical history with regard to duration of renal failure (In years), diabetes/hypertension if any, and whether the patients undergoing dialysis or erythropoietin replacement was used. Height, weight and blood pressure was noted in all patients. Laboratory tests including serum creatinine, Hb, Hct, calcium, creatinine clearance (calculated according to creatinine clearance by Cockcroft-Gault equation. Calculation of left ventricular mass: As, both body size and body habitus are clearly associated with left ventricle dimension and mass, indexing for body size is required. Left ventricular mass index was calculated by using the ratio of left ventricle mass to body surface area left ventricle mass was derived by Modified Devereux formula using 2D Echocardiography.

Left ventricle Mass = $0.8 \times 1.04 (IVSd + LVIDd + LVPWd) \times 3 - (LVIDd) \times 3 + 0.6$ gms

Where IVSd = interventricular thickness in diastole in mm; LVID; d = left ventricular diameter in diastole in mm; LVPWd = left ventricular posterior wall thickness in diastole in mm, left ventricular hypertrophy is categorically defined as left ventricular mass index >135 for males and >110 for females.

Statistical Analysis

In our study, all patients had haemoglobin <11 g/dl. Looking into Indian perspective where poor diet, chronic infections and malnourishment is common, and for convenience of our study, we took Hb <8 g/dl as reference value and were taken as anemic in both male and female. Chi-square test was applied to find relationship between the variables and odds ratio was calculated to determine the risk of abnormal values as compared to the normal values, $p < 0.05$ was taken to be significant.

Results

Table 1: Age and Gender wise distribution of study population and distribution of normal and abnormal left ventricular mass index among male patients

Age groups (years)		N	%
15-30		25	25
31-45		20	20
46-60		34	34
61-75		16	16
>75		5	5
Gender			
Male		68	68
Female		32	32
Gender	Left ventricular mass index (gm/m ²)	N	%
Male	<135 (Normal)	18	26.48
	>135 (Abnormal)	50	73.52
Female	<110 (Normal)	4	12.5
	>110 (Abnormal)	28	87.5

Majority of study population i.e. 68% was male, 32% was female. Most of the male patient, i.e. 73.52% of the study population, have abnormal left ventricular mass index (135 g/m² is taken as normal value for male patients). Majority of female patients i.e., 87.5% have abnormal left ventricular mass index. 34% patients belonged to 46-60 years age group.

Table 2: Hb with left ventricular mass index in males and females

Variables	Hb<8	Hb>8	Odds ratio	95% CI	P value
Left ventricular mass index (male)					
<135	5	12	0.040	0.0047-0.3350	0.002
>135	30	21			
Left ventricular mass index (female)					
<110	6	6	0.067	0.0081-0.2940	0.03
>110	10	10			

Relation of anemia (Reference value for this study population being taken as 8 g/dl with left ventricular mass index in both male and female patients of study population, p value is significant for both male and female population. There was strong correlation between Anemia and left ventricular mass index in both male and female patients.

Table 3: Diabetes mellitus verses LVMI

Variables	Present	Absent
Male		
LVMI		
<135	5	10
>135	15	38
Female		
LVMI		
<110	0	2
>110	2	28

17 out of 22 patients who were diabetic are having abnormal LVMI, whereas 66 out of 78 non-diabetic patients have abnormal LVMI, so there is no correlation between DM and LVMI.

Discussion

The incidence and prevalence of chronic kidney disease (CKD) are on the rise globally and it has grown into an important public health problem [8]. The ultimate outcome of CKD in majority of patients is End Stage Renal Disease (ESRD) requiring renal replacement therapy (RRT), which necessitates ever-growing dialysis and transplants and imposes huge economic burden on the healthcare systems [9]. The social and financial inferences of CKD are considerable not only because of morbidity and mortality, related to its conversion to ESRD, but also with accelerated cardiovascular disease (CVD) [10, 11]. Cardiovascular Disease is the leading cause of mortality in patients with CKD accounting for 10 to 100 times higher in Hemodialysis patients [12]. It is important to note that the majority of patients with CKD die of CVD before reaching ESRD [13]. LVH is the most prominent structural cardiovascular alteration in CKD patients and is found in approximately 30 to 45 percent of patients with CKD and more severe LVH is noted with decreasing glomerular filtration rate (GFR) [14, 15]. Majority of study population i.e. 68% was male, 32% was female. Most of the male patient, i.e. 73.52% of the study population, have abnormal left ventricular mass index (135 g/m² is taken as normal value for male patients). Majority of female patients i.e., 87.5% have abnormal left ventricular mass index. 34% patients belonged to 46-60 years age group. Left ventricular hypertrophy was measured using echocardiography of heart by using Devereux formula [16]. Around 79% of the patients in this study had increased left ventricular mass on echocardiography. The limit for left ventricular hypertrophy for females was >110 g/m². 31.05% of the female cases had increased left ventricular mass. 47.5% of the male cases had increased left ventricular mass according to Devereux formula. In our study, there is association between different age groups and increased left ventricular mass. The difference between the age groups for normal and abnormal left ventricular mass index was statistically significant for male. In a study by Hamett *et al.* the age was associated with the development of left ventricular hypertrophy after the initiation of dialysis [17]. They found that cases that developed left ventricular hypertrophy were significantly older than controls at baseline; the reason cited was that the aging ventricle is more sensitive to the hypertrophic stimulus of an elevated systolic blood pressure. There was significant relation between anemia with left ventricular mass index in both male and female patients. The reference value taken was 8 g/dl for Hb [18, 19].

Relation of anemia (reference value for this study population being taken as 8 g/dl with left ventricular mass index in both male and female patients of study population, p value is significant for both male and female population. There was strong correlation between Anemia and left ventricular mass index in both male and female patients. 17 out of 22 patients who were diabetic are having abnormal LVMI, whereas 66 out of 78 non-diabetic patients have abnormal LVMI, so there is no correlation between DM and LVMI. In our study, hypertensive patients who were under control with medications were taken as the study population; to eliminate the bias of uncontrolled hypertension inducing left ventricular hypertrophy. Elevated systolic blood pressure is a well-known independent factor for left ventricular mass index. Severity of anaemia could very well predict the left ventricular dimension and thickness in both male as well as female patients, and therefore risk of CVDs [20, 21]. This study points towards importance of timely administration of anaemia-correcting measures in form of EPO or blood transfusion which could herald or reverse left ventricle remodelling. In the study by Jesuorobo *et al.* the hemoglobin levels of the study population had a negative correlation with left ventricular mass index and it was statistically significant [22].

Conclusion

Severity of anemia significantly influences the left ventricular wall thickness in chronic kidney disease patients. These predictors of left ventricle mass could be easily measured and are highly sensitive and specific for the same. On arriving at a suspicion of possible left ventricle hypertrophy, rigorous measures should be taken to correct anemia by EPO with or without iron administration and blood transfusion, to improve the patient's survival from the deadly cardiovascular diseases.

References

1. Kansz AT, Khan SS, Abichandani R. Management of patients with chronic renal insufficiency in the Northeastern United States. *J Am Soc Nephrol.* 2001;7:1501-1507.
2. Harnett JD, Kent GM, Foley RM, Parfrey PS. Cardiac function and hematocrit level. *Am J Kidney Dis.* 1995;25:S3-7.
3. Levin A, Thompson CR, Ethier J. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. *Am J Kidney Dis.* 1999;34:125-134.
4. Foley RN, Parfrey PS, Harnett JD. The impact of anemia on cardiomyopathy, morbidity and mortality in ESRD. *Am J Kidney Dis.* 1996;28:53-61.
5. Daniel E Weiner, Hocine Tighioutart, Panagiotis T Vlagopoulos, John L Griffith, Deeb N Salem, Andrew S Levey, *et al.* Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. 2005 Jun;16(6):1803-1810.
6. Zoccali C. Arterial pressure components and cardiovascular risk in end-stage renal disease *Nephrol Dial Transplant.* 2003;18:249-252.
7. Datta S, Abraham G, Mathew M, Somasundaram H, Muralidharan TR, Moorthy A, *et al.* Correlation of anemia, secondary hyperparathyroidism with left ventricular hypertrophy in chronic kidney disease patients. *The Journal of the Association of Physicians of India.* 2006 Sep 1;54:699-703.

8. Hemmelgarn BR, James MT, Manns BJ, O'Hare AM, Muntner P, Ravani P, *et al.* Alberta Kidney Disease Network. Rates of treated and untreated kidney failure in older vs younger adults. *Jama*. 2012 Jun 20;307(23):2507-2515.
9. Centres for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. *MMWR. Morbidity and mortality weekly report*. 2007 Mar 2;56(8):161.
10. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, *et al.* Chronic kidney disease: Global dimension and perspectives. *The Lancet*. 2013 Jul 20;382(9888):260-272.
11. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. *Kidney international*. 2011 Dec 2;80(12):1258-1270.
12. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, *et al.* Prevalence of chronic kidney disease in China: a cross-sectional survey. *The Lancet* 2012;379(9818):815-822.
13. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. *The Lancet*. 2011 Jun 25;377(9784):2181-2192.
14. Moran A, Katz R, Jenny NS, Astor B, Bluemke DA, Lima JA, *et al.* Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: The multi-ethnic study of atherosclerosis (MESA). *American Journal of kidney diseases*. 2008 Nov 1;52(5):839-848.
15. Nardi E, Palermo A, Mule G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. *Journal of hypertension*. 2009 Mar 1;27(3):633-641.
16. Richard DB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. *Circulation*. 1977;55(4):613-618.
17. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. *Journal of the American Society of Nephrology*. 1994 Jan 1;4(7):1486-1490.
18. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. *Journal of the American Society of Nephrology*. 2004 Jun 1;15(6):1640-1647.
19. Yilmaz BA. Predictors of left ventricular hypertrophy in patients with chronic kidney disease. *Ren Fail*. 2007;29(3):303-307.
20. Cao XS. BMI, spKt/V, and SBP but Not DBP Are Related to LVH in Chinese maintenance hemodialysis patients. *Renal Failure*. 2011;33(3):269-275.
21. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. *Clinical Journal of the American Society of Nephrology*. 2010 May 1;5(5):805-813.
22. Jesuorobo DE. Left ventricular hypertrophy and its correlates in chronic kidney disease patients in a Nigerian tertiary hospital. *Intern J Intern Med*. 2012;1(3):11-16.

How to Cite This Article

K Faraz. An observational study assessing correlation between anemia and left ventricular hypertrophy in chronic kidney disease patients. *International Journal of Research in Medical Science*. 2023;5(1):25-28.

Creative Commons (CC) License

This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.